Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Structured treatment interruption in HIV infection.

C A Benson1

  • 1Division of Infectious Diseases, University of Colorado Health Sciences Center, Denver, USA.

The AIDS Reader
|March 31, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention.

The Journal of antimicrobial chemotherapy·2020
Same author

Cerebral organoids reveal early cortical maldevelopment in schizophrenia-computational anatomy and genomics, role of FGFR1.

Translational psychiatry·2018
Same author

Digitizing Medicines for Remote Capture of Oral Medication Adherence Using Co-encapsulation.

Clinical pharmacology and therapeutics·2017
Same author

Common developmental genome deprogramming in schizophrenia - Role of Integrative Nuclear FGFR1 Signaling (INFS).

Schizophrenia research·2017
Same author

Improved tuberculosis outcomes with daily vs. intermittent rifabutin in HIV-TB coinfected patients in India.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2016
Same author

"Nuclear FGF receptor-1 and CREB binding protein: an integrative signaling module".

Journal of cellular physiology·2014
Same journal

Effect of antiretroviral resistance on response in treatment-experienced patients.

The AIDS reader·2009
Same journal

Maximizing treatment outcome: key considerations for antiretroviral-experienced patients.

The AIDS reader·2009
Same journal

Utilizing a new class of antiretrovirals: role of fusion inhibitors in HIV disease management.

The AIDS reader·2009
Same journal

Economic crisis threatens AIDS fight.

The AIDS reader·2009
Same journal

Editorial comment: mixing tenofovir with other nephrotoxins--how safe is this?

The AIDS reader·2009
Same journal

Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.

The AIDS reader·2009
See all related articles

Structured treatment interruptions for HIV infection aim to boost immune responses but carry significant risks. Long-term benefits remain unproven, with dangers including drug resistance and opportunistic infections.

Area of Science:

  • Immunology
  • Virology
  • Infectious Diseases

Background:

  • Treatment interruptions (TIs) have been studied in acute and chronic HIV infection.
  • TIs are also evaluated before initiating multidrug salvage therapy for HIV.
  • The goal is to stimulate or preserve HIV-specific immune responses.

Purpose of the Study:

  • To evaluate the efficacy and risks of structured treatment interruptions in HIV management.
  • To assess immune stimulation and viral response to TIs in different HIV infection stages.

Main Methods:

  • Review of studies on structured and unstructured treatment interruptions in HIV.
  • Analysis of immune responses (CD4 T cells, CTLs) and viral load dynamics.
  • Examination of outcomes before multidrug salvage therapy.

Related Experiment Videos

Main Results:

  • TIs can stimulate immune responses in acute HIV infection, but long-term benefits are unproven.
  • Interruptions before salvage therapy may lead to drug-susceptible virus reemergence.
  • Potential dangers include acute retroviral syndrome, drug resistance, CD4 decline, and opportunistic infections.

Conclusions:

  • The long-term clinical benefits of structured treatment interruptions for HIV are not established.
  • Potential risks associated with TIs are significant and not merely theoretical.
  • Careful consideration of risks versus benefits is crucial in HIV treatment strategies involving interruptions.